Aiming to best at the end
Algeta hopes Alpharadin will be preferred in late-stage prostate cancer
Although four new drugs have come to market for castration-resistant prostate cancer since April 2010, Algeta ASA thinks there will be room for its Alpharadin radium-223 chloride to replace taxanes in the sickest patients.
Data from the Phase III ALSYMPCA trial reported this month showed an improvement in overall survival compared to placebo. But Alpharadin's real advantage may be that it provides better quality of life for these end-of-life patients than the taxanes that are current standard of care.
Three of the new drugs are primarily focused on early stage, asymptomatic CRPC.
One of these is Provenge sipuleucel-T, an